Literature DB >> 27297494

Specific age-related molecular alterations in the cerebellum of Down syndrome mouse models.

Nicole Créau1, Eva Cabet2, Fabrice Daubigney2, Benoit Souchet2, Soumia Bennaï2, Jean Delabar2.   

Abstract

Down syndrome, or trisomy 21, has been modeled with various trisomic and transgenic mice to help understand the consequences of an altered gene dosage in brain development and function. Though Down syndrome has been associated with premature aging, little is known about the molecular and cellular alterations that target brain function. To help identify alterations at specific ages, we analyzed the cerebellum of Ts1Cje mice, trisomic for 77 HSA21 orthologs, at three ages-young (4 months), middle-age (12 months), and old (17 months)-compared to age-matched controls. Quantification of neuronal and glial markers (n=11) revealed increases in GFAP, with an age effect, and S100B, with age and genotype effects. The genotype effect on S100B with age was unexpected as Ts1Cje has only two copies of the S100b gene. Interestingly, the different increase in GFAP observed between Ts1Cje (trisomic segment includes Pcp4 gene) and controls was magnified in TgPCP4 mice (1 extra copy of the human PCP4 gene) at the same age. S100B increase was not found in the TgPCP4 confirming a difference of regulation with aging for GFAP and S100B and excluding the calcium signaling regulator, Pcp4, as a potential candidate for increase of S100B in the Ts1Cje. To understand these differences, comparison of GFAP and S100B immunostainings at young and middle-age were performed. Immunohistochemical detection of differences in GFAP and S100B localization with aging implicate S100B+ oligodendrocytes as a new phenotypic target in this specific aging process.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Aging; Cerebellum; Down syndrome; S100B; Ts1Cje

Mesh:

Substances:

Year:  2016        PMID: 27297494     DOI: 10.1016/j.brainres.2016.06.003

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  5 in total

Review 1.  Targeting trisomic treatments: optimizing Dyrk1a inhibition to improve Down syndrome deficits.

Authors:  Megan Stringer; Charles R Goodlett; Randall J Roper
Journal:  Mol Genet Genomic Med       Date:  2017-09-20       Impact factor: 2.183

2.  Altered age-linked regulation of plasma DYRK1A in elderly cognitive complainers (INSIGHT-preAD study) with high brain amyloid load.

Authors:  Jean M Delabar; Marion Ortner; Stephanie Simon; Anne Wijkhuisen; Cecile Feraudet-Tarisse; Jonathan Pegon; Emma Vidal; Yael Hirschberg; Bruno Dubois; Marie-Claude Potier
Journal:  Alzheimers Dement (N Y)       Date:  2020-07-02

Review 3.  Astroglial and microglial pathology in Down syndrome: Focus on Alzheimer's disease.

Authors:  Octavio García; Lisi Flores-Aguilar
Journal:  Front Cell Neurosci       Date:  2022-09-20       Impact factor: 6.147

4.  Analysis of motor dysfunction in Down Syndrome reveals motor neuron degeneration.

Authors:  Sheona Watson-Scales; Bernadett Kalmar; Eva Lana-Elola; Dorota Gibbins; Federica La Russa; Frances Wiseman; Matthew Williamson; Rachele Saccon; Amy Slender; Anna Olerinyova; Radma Mahmood; Emma Nye; Heather Cater; Sara Wells; Y Eugene Yu; David L H Bennett; Linda Greensmith; Elizabeth M C Fisher; Victor L J Tybulewicz
Journal:  PLoS Genet       Date:  2018-05-10       Impact factor: 5.917

5.  Neuronal overexpression of Alzheimer's disease and Down's syndrome associated DYRK1A/minibrain gene alters motor decline, neurodegeneration and synaptic plasticity in Drosophila.

Authors:  Simon A Lowe; Maria M Usowicz; James J L Hodge
Journal:  Neurobiol Dis       Date:  2019-01-28       Impact factor: 5.996

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.